Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
(Q33899917)
scientific article
scientific article
Language:
Current Data About
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.